Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | CAL-101 | 2 | 72 | 0.01 | 3257.5 | 3469.3 | 1018.6 | -2.0 | 0.930 | 0.939 | 1.768 | BT20 CAL101 0 2 |
BT-20 | CAL-101 | 2 | 72 | 0.032 | 3284.0 | 3469.3 | 1018.6 | -1.49 | 0.939 | 0.947 | 1.768 | BT20 CAL101 0 2 |
BT-20 | CAL-101 | 2 | 72 | 0.1 | 3213.0 | 3469.3 | 1018.6 | -1.0 | 0.915 | 0.926 | 1.768 | BT20 CAL101 0 2 |
BT-20 | CAL-101 | 2 | 72 | 0.32 | 3269.3 | 3469.3 | 1018.6 | -0.495 | 0.934 | 0.942 | 1.768 | BT20 CAL101 0 2 |
BT-20 | CAL-101 | 2 | 72 | 1.0 | 3064.8 | 3469.3 | 1018.6 | 0.0 | 0.865 | 0.883 | 1.768 | BT20 CAL101 0 2 |
BT-20 | CAL-101 | 2 | 72 | 3.2 | 2930.8 | 3469.3 | 1018.6 | 0.505 | 0.818 | 0.845 | 1.768 | BT20 CAL101 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.001 | 1803.0 | 3213.5 | 1018.6 | -3.0 | 0.411 | 0.561 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.0032 | 1773.8 | 3213.5 | 1018.6 | -2.49 | 0.397 | 0.552 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.01 | 1863.0 | 3213.5 | 1018.6 | -2.0 | 0.439 | 0.580 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.032 | 1675.5 | 3213.5 | 1018.6 | -1.49 | 0.350 | 0.521 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.1 | 1800.3 | 3213.5 | 1018.6 | -1.0 | 0.410 | 0.560 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 0.32 | 1752.8 | 3213.5 | 1018.6 | -0.495 | 0.387 | 0.545 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 1.0 | 1591.0 | 3213.5 | 1018.6 | 0.0 | 0.309 | 0.495 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Everolimus | 2 | 72 | 3.2 | 1212.8 | 3213.5 | 1018.6 | 0.505 | 0.111 | 0.377 | 1.658 | BT20 Everolimus 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.001 | 2270.3 | 3416.0 | 1018.6 | -3.0 | 0.583 | 0.665 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.0032 | 2966.0 | 3416.0 | 1018.6 | -2.49 | 0.845 | 0.868 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.01 | 3176.8 | 3416.0 | 1018.6 | -2.0 | 0.919 | 0.930 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.032 | 2994.5 | 3416.0 | 1018.6 | -1.49 | 0.855 | 0.877 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.1 | 2930.8 | 3416.0 | 1018.6 | -1.0 | 0.832 | 0.858 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 0.32 | 2142.8 | 3416.0 | 1018.6 | -0.495 | 0.531 | 0.627 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 1.0 | 1217.8 | 3416.0 | 1018.6 | 0.0 | 0.108 | 0.356 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | Pictilisib | 2 | 72 | 3.2 | 927.8 | 3416.0 | 1018.6 | 0.505 | -0.052 | 0.272 | 1.746 | BT20 GDC0941 0 2 |
BT-20 | GDC-0980 | 2 | 72 | 0.001 | 3333.5 | 3217.8 | 1018.6 | -3.0 | 1.040 | 1.040 | 1.659 | BT20 GDC0980 0 2 |
BT-20 | GDC-0980 | 2 | 72 | 0.0032 | 3107.8 | 3217.8 | 1018.6 | -2.49 | 0.959 | 0.966 | 1.659 | BT20 GDC0980 0 2 |
BT-20 | GDC-0980 | 2 | 72 | 0.01 | 3079.3 | 3217.8 | 1018.6 | -2.0 | 0.948 | 0.957 | 1.659 | BT20 GDC0980 0 2 |